During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...

A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

Number 4: In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes ...